GSK poaches new drug development chief Chris Corsico from Boehringer, dividing R&D into two groups
GlaxoSmithKline is continuing its makeover in the executive team that runs its R&D group.
The pharma giant tells me that Chris Corsico, who had been chief medical officer at the private German outfit Boehringer Ingelheim, is stepping over to GSK as the head of drug development, putting him in a new, top position for hammering out the clinical plans that the pharma giant is putting into place under R&D chief Hal Barron.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.